

Ingo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10135497/publications.pdf>

Version: 2024-02-01

52
papers

902
citations

567144

15
h-index

526166

27
g-index

52
all docs

52
docs citations

52
times ranked

1549
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. <i>Blood</i> , 2014, 124, 3870-3879.	0.6	236
2	Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2020, 235, 9291-9303.	2.0	59
3	Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2014, 15, 14632-14648.	1.8	48
4	Severe Abdominal Infections in Neutropenic Patients. <i>Cancer Investigation</i> , 2001, 19, 669-677.	0.6	38
5	Targeting the Wnt/beta-catenin pathway in renal cell carcinoma. <i>Anticancer Research</i> , 2014, 34, 4101-8.	0.5	34
6	Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. <i>BMC Cancer</i> , 2020, 20, 355.	1.1	33
7	Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4307.	1.8	30
8	30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 388.	3.5	26
9	Prevalence, Supplementation, and Impact of Vitamin D Deficiency in Multiple Myeloma Patients. <i>Cancer Investigation</i> , 2015, 33, 505-509.	0.6	25
10	Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2018, 2, 1-9.	2.5	25
11	Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma. <i>Hematological Oncology</i> , 2017, 35, 719-725.	0.8	24
12	Effect of Wnt inhibitors in pancreatic cancer. <i>Anticancer Research</i> , 2014, 34, 5375-80.	0.5	21
13	Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2471.	1.7	20
14	Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma. <i>Neurology</i> , 2020, 95, e3138-e3144.	1.5	18
15	Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3078.	1.8	16
16	Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. <i>European Journal of Haematology</i> , 2017, 99, 42-50.	1.1	15
17	Epigenetic Regulatory Enzymes: mutation Prevalence and Coexistence in Cancers. <i>Cancer Investigation</i> , 2021, 39, 257-273.	0.6	15
18	Increase of Antitumoral Effects of Cytokine-Induced Killer Cells by Antibody-Mediated Inhibition of MICA Shedding. <i>Cancers</i> , 2020, 12, 1818.	1.7	14

#	ARTICLE	IF	CITATIONS
19	Utilizing ethacrynic acid and ciclopirox olamine in liver cancer. <i>Oncology Letters</i> , 2018, 16, 6854-6860.	0.8	13
20	Alpha-Fetoprotein- and CD40Ligand-Expressing Dendritic Cells for Immunotherapy of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 3375.	1.7	11
21	Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide. <i>Anticancer Research</i> , 2017, 37, 555-560.	0.5	11
22	Recent Development in NKT-Based Immunotherapy of Glioblastoma: From Bench to Bedside. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1311.	1.8	11
23	Improvements in Flow Cytometry-Based Cytotoxicity Assay. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 680-688.	1.1	10
24	Fluorescent Probes for Ecto-5'-nucleotidase (CD73). <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 2253-2260.	1.3	10
25	High Expression of Cannabinoid Receptor 2 on Cytokine-Induced Killer Cells and Multiple Myeloma Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3800.	1.8	10
26	The value of bone marrow biopsy for staging of patients with primary CNS lymphoma. <i>Neuro-Oncology</i> , 2021, 23, 2076-2084.	0.6	9
27	PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines. <i>Oncology Letters</i> , 2021, 22, 613.	0.8	9
28	NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation. <i>Frontiers in Immunology</i> , 2021, 12, 731767.	2.2	9
29	Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. <i>Cancer Investigation</i> , 2016, 34, 361-372.	0.6	8
30	CIK Cells and HDAC Inhibitors in Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2017, 18, 945.	1.8	8
31	Flunarizine exhibits in vitro efficacy against lymphoma and multiple myeloma cells. <i>Anticancer Research</i> , 2015, 35, 1369-76.	0.5	8
32	A Low Dose of Pure Cannabidiol Is Sufficient to Stimulate the Cytotoxic Function of CIK Cells without Exerting the Downstream Mediators in Pancreatic Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3783.	1.8	8
33	Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 2205-2212.	1.2	7
34	In Vitro Apoptosis Induction by Fenofibrate in Lymphoma and Multiple Myeloma. <i>Anticancer Research</i> , 2017, 37, 3513-3520.	0.5	7
35	Clinical Studies on Cytokine-Induced Killer Cells: Lessons from Lymphoma Trials. <i>Cancers</i> , 2021, 13, 6007.	1.7	6
36	In vitro efficacy of cinnarizine against lymphoma and multiple myeloma. <i>Anticancer Research</i> , 2015, 35, 835-41.	0.5	6

#	ARTICLE	IF	CITATIONS
37	Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLapsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma. <i>BMC Cancer</i> , 2016, 16, 290.	1.1	5
38	A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center. <i>BMC Cancer</i> , 2019, 19, 1024.	1.1	5
39	Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study. <i>Journal of Clinical Oncology</i> , 2014, 32, e15590-e15590.	0.8	5
40	Immune Check Point CD40/CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells. <i>Anticancer Research</i> , 2019, 39, 4643-4652.	0.5	4
41	Questions and emotional expressions from patients and companions while participating in multidisciplinary tumor conferences in breast and gynecological cancer centers. <i>Patient Education and Counseling</i> , 2022, 105, 2058-2066.	1.0	4
42	Increased effect of IMiDs by addition of cytokine-induced killer cells in multiple myeloma. <i>Hematological Oncology</i> , 2016, 34, 208-216.	0.8	3
43	No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany. <i>BMC Cancer</i> , 2021, 21, 526.	1.1	3
44	Effect of chaetocin on renal cell carcinoma cells and cytokine-induced killer cells. <i>GMS German Medical Science</i> , 2016, 14, Doc04.	2.7	3
45	Efficacy of cytokine-induced killer cells targeting CD40 and GITR. <i>Oncology Letters</i> , 2018, 17, 2425-2430.	0.8	2
46	PPAR-Responsive Elements Enriched with Alu Repeats May Contribute to Distinctive PPAR γ -DNMT1 Interactions in the Genome. <i>Cancers</i> , 2021, 13, 3993.	1.7	2
47	Matched-pair analysis of dendritic cell versus targeted-therapy in patients with metastatic renal cell carcinoma. <i>Anticancer Research</i> , 2015, 35, 1575-82.	0.5	2
48	In Vitro Efficacy of Naftifine Against Lymphoma and Multiple Myeloma. <i>Anticancer Research</i> , 2015, 35, 5921-6.	0.5	2
49	Clofibrate Demonstrates Efficacy in In Vitro Treatment of Lymphoma and Multiple Myeloma. <i>Anticancer Research</i> , 2016, 36, 3395-400.	0.5	2
50	Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics. <i>Investigational New Drugs</i> , 2020, 38, 1717-1729.	1.2	1
51	Griseofulvin Efficiently Induces Apoptosis in Treatment of Lymphoma and Multiple Myeloma. <i>Anticancer Research</i> , 2017, 37, 2289-2295.	0.5	1
52	Presence of the Transmembrane Protein Neuropilin in Cytokine-induced Killer Cells. <i>Anticancer Research</i> , 2020, 40, 5489-5496.	0.5	0